Genmab regains rights to HuMax-TAC

Genmab A/S announced today it has regained all rights to the HuMax-TAC™ antibody from Merck Serono following a portfolio review by Merck Serono

COPENHAGEN, Denmark | August 2, 2007 | Genmab A/S (OMX: GEN) announced today it has regained all rights to the HuMax-TAC™ antibody from Merck Serono following a portfolio review by Merck Serono. Worldwide rights to HuMax-TAC were previously licensed to Merck Serono in May 2005. Regaining the rights to HuMax-TAC will not influence Genmab’s financial guidance for 2007.

“Now that we have regained rights to the HuMax-TAC program, Genmab will review the program internally to decide on future plans,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.SOURCE: Genmab A/S

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top